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To maximise the likelihood of success, global health programmes need repeated, honest appraisal of their own
weaknesses, with research undertaken to address any identified gaps. There is still much to be learned to opti-
mise work against neglected tropical diseases. To facilitate that learning, a comprehensive research and devel-
opment plan is required. Here, we discuss how such a plan might be developed.
Impressive progress has been made against neglected tropi-
cal diseases (NTDs) since the publication of the first NTD road
map1 and the London Declaration on NTDs2 in 2012. At least one
NTD has been eliminated from 40 countries, territories or areas,
500 million fewer people require interventions against NTDs3
and effective oral treatment regimens have become available
for Buruli ulcer, yaws and stage 2 human African trypanosomia-
sis due to Trypanosoma gambiense.4-6 The 2021–2030 NTD road
map,3 which is awaiting World Health Assembly endorsement,
seeks to build upon this progress by setting or reaffirming a num-
ber of ambitious targets, including elimination of at least one NTD
from 100 countries and global eradication of yaws and dracun-
culiasis.
As we pursue these targets over the next 10 years it will be
important to learn fromprevious elimination and eradication pro-
grammes. The yaws eradication programme, launched by the
WHO in 1952, was hugely successful, examining 460million peo-
ple, treating more than 50 million and reducing the global preva-
lence of yaws by >95%. However, as prevalence fell and trans-
mission interruption was approached in many countries, funding
became increasingly hard to obtain. Postelimination surveillance
was not established and the disease subsequently returned.7
The endgamemay be the most difficult part of an elimination
programme. It can be frustrating. In the case of Guinea-worm
disease, the number of new cases was reduced frommore than 3
million per year in the 1980s to 28 in 2018, but in 2019, 54 human
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cases were reported, including one in Angola, a country that had
only ever reported one previous human case.8 In Chad, nearly
1500 infected dogs were identified; to eliminate this reservoir,
research is needed to understand how dogs are infected and how
infection can be prevented.9 In the case of trachoma, where the
definition of elimination is based on prevalence of physical signs,
it has become increasingly difficult to train healthcare workers to
identify cases as cases become less common; in addition, in some
populations, the signs are not specific and many individuals have
follicular conjunctivitis not due to trachoma. Recent research has
focused on the potential use of serology to determine whether
transmission of ocular Chlamydia trachomatis infection has been
reduced sufficiently to make future trachoma-related blindness
unlikely.10
To have confidence that elimination targets have been met,
large numbers of people (and, in the case of some vector-borne
diseases, large numbers of vectors) must be tested.11-13 The cost
of such efforts is not insignificant.14 New, high-throughput diag-
nostic tests are required, some of which will need to work effi-
ciently at point-of-human-care or be useful for testing interme-
diate or reservoir hosts. Tests must be highly specific (to avoid
confusion due to false positives) and sensitive enough to detect
the few remaining cases. Target product profiles for diagnostics
for mapping and monitoring some NTDs, and for postelimination
surveillance, were published in 201215 but need to be updated,
and should facilitate development of integrated multi-disease
testing platforms to increase the cost-effectiveness of monitor-
ing. Development of updated diagnostic target product profiles is
now being undertaken by WHO’s recently established NTD Diag-
nostics Technical Advisory Group. Political, financial and techni-
cal investment to fully capacitate laboratories will be essential
for undertaking the requisite studies plus routine testing.
In the case of lymphatic filariasis, for example, the traditional
diagnostic method of identifying microfilariae in blood samples
was recognised as imperfect, since in many places it requires
night-time blood collection (because of the nocturnal periodicity
ofmicrofilariae) and subsequent painstakingmicroscopy. A point-
of-care serological test for circulating filarial antigen (CFA) was
therefore developed and is now used to validate elimination; the
elimination target is a prevalence of CFA positivity of <2.0% in
children aged 6–8 y, persisting for at least 4 y after cessation of
mass treatment.
For some other NTDs, the endgame feels a long way away.
Mycetoma, chromoblastomycosis and other deep mycoses were
added to theWHO’s NTD list in 2016; snakebite envenoming, and
scabies and other ectoparasites, were added in 2017. Develop-
ment of comprehensive packages of epidemiological assessment
and public health intervention for these conditions is at an early
stage.16-19 For yaws, the geographical extent of the endemic
population and the required number of rounds of mass treat-
ment to interrupt transmission are each far from certain,20,21 and
both macrolide resistance and infection in non-human primates
put eradication at risk. Due to multiple factors including popula-
tion growth, enhanced travel, urbanisation and expansion in the
range of the vector mosquitoes, the global incidence of dengue
is increasing year on year.22 For soil-transmitted helminthiases
and schistosomiasis, reinfection may be rapid after preventive
chemotherapy applied alone; programmes may need other
effective interventions to maximise their impact.23,24
Compounding these complexities is the local amplification of
NTD transmission by multiple forces, including war and political
collapse,25 urbanisation26 and shifting poverty. Climate change
is also affecting the geographical distribution of multiple NTDs.
Since 2020, the COVID-19 pandemic threatens the progress of
NTD programmes through multiple mechanisms.
To help combat these challenges, we must face the reality
that, in addition to better diagnostics, we urgently need new and
improved NTD vaccines and drugs. The dramatic acceleration of
work to generate analogous tools against COVID-19 is a clear sig-
nal that we could achieve similar progress in NTD science if we
had the requisite political will and drive.27
A comprehensive research and development blueprint could
help address these challenges by allowing scientists and donors
to contribute in a more coordinated way. How would we, as an
extended NTD community, develop such a blueprint and make it
maximally effective for driving change?
The answer is likely to be a combination of actions and atti-
tudes. The list includes: an awareness of history; synthesis and
honest evaluation of existing evidence; modelling of current pro-
gramme trajectories and probable future needs; frank conver-
sations involving all relevant stakeholders; the recognition that
effort has already been invested in curating research priorities for
some diseases,18,28-30 forming possible starting points for compi-
lation of a more comprehensive research agenda; hard work; col-
laboration; research capacity-building in NTD-endemic countries;
and a willingness to review, reflect and change as things evolve.
The hard work has already started. The WHO has recog-
nised the listing of identified NTD research priorities within its
Global Observatory on Health research and development plat-
form (https://www.who.int/research-observatory/en/) to be a
Global Public Health Good, allowing internal resources to be
devoted to the task. And it has commenced an internal review
of existing lists of disease-specific research priorities, including
those contained in the 2021–2030 roadmap. The weaknesses of
existing lists include a lack of clarity on and consistency in the
approach to their development, and differences in the structuring
of prioritised questions across diseases, which could limit thinking
about the integration of research and programmes.
Dedicated research to support the integration agenda is
overdue.31 All elements of NTD programmes—including pro-
gramme management, epidemiological assessment, disease
control and evaluation—could potentially benefit. Integration
could include linking co-endemic NTDs, better connecting NTD
programmes with efforts against other communicable and non-
communicable diseases, as well as joining forces with develop-
ment programmes outwith the health sector.
Cross-cutting socioanthropological and health systems
research is also needed to guide programmes on how and
when to deliver new (and existing) tools to end-of-the-road
communities in the most cost-effective way. Regardless of their
quality, commodities do not deliver themselves. Implementation
research is key to ensuring that the time and money invested in
other research and programmatic elements are not wasted.
Consultation to gather input from the wider NTD community
will be undertaken in 2020. In the altered world of the COVID-
19 pandemic, convening an inclusive forum to undertake this
process may be more straightforward than it might otherwise
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in which the strength of ideas matters more than stridency of
speech, and the involvement of greater numbers of more diverse
constituencies becomes possible with marked reductions in the
cost of meeting attendance.
In themeantime, while a research and development blueprint
is being developed and the questions it identifies are being
answered, work to alleviate the suffering caused by NTDs should
not stop. We already have many proven, cost-effective interven-
tions. To this end, we should continue to strike a measured bal-
ance between expressing confidence in the valuable tools thatwe
already have and the uncertainty elsewhere thatwill drive further
progress. For that, skilled and credible advocates will be needed,
as well as partners willing to hear a complicated tale.
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